IP Library Granted Patent US 8,541,476
Granted Patent B2
US 8,541,476 · App. 12/677,478 · Granted Sep 24, 2013

Compounds for treatment of malignant tumors

Inventors: Constantinos Koumenis (Philadelphia, PA); Brian E. Lally (Miami, FL); Steven Kridel (Clemmons, NC); Gary D. Kao (Wynnewood, PA); Adeboye Adejare (Mantua, NJ)
Assignees: The Trustees of the University of Pennsylvania; Wake Forest University Health Sciences; University of the Sciences in Philadelphia
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,541,476
App. No.
12/677,478
Granted
Sep 24, 2013
Kind
B2
Abstract

The present invention comprises compounds, compositions and methods of use for sensitizing cancer cells, tumors, neoplasms, and malignancies to the effects of ionizing radiation used in the treatment of cancer. The invention further comprises a method of identifying novel radiosensitizing compounds.

Claims (30)

1. A method of treating a mammal diagnosed with cancer, said method comprising administering to said mammal a therapeutically effective amount of a pharmacological composition comprising a compound of formula (I):

wherein:

Y is NO 2 , NR 1 3 , CN, CHO, C(O)R 1 or CF 3 ;

X is H, F, Cl, Br or I;

R is CN, CHO, C(O)R 1 , C(O)NH 2 , C(O)NHR 1 , C(O)NR 1 R 2 , S(O) m R 1 , S(O) 2 NH 2 , S(O) 2 NHR 1 , S(O) 2 NR 1 R 2 , P(O)(OH)R 1 , C(O)OH, or C(O)OR 1 ;

R 1 and R 2 each independently is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 , CH 2 CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , or C(CH 3 ) 3 ; and

m is an integer of 0, 1 or 2;

or a pharmaceutically acceptable salt,

wherein said composition contacts a cancer cell or tumor in said mammal, thereby making said cancer cell or tumor more susceptible to the effects of ionizing radiation,

wherein said cancer is at least one selected from the group consisting of glioma, colorectal cancer and non-small cell lung cancer.

2. The method of claim 1 , wherein said composition is administered before, during, or after said mammal receives radiation therapy, or a combination thereafter.

3. The method of claim 1 , wherein said mammal is a human.

4. A method of treating a mammal diagnosed with cancer, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising Formula I,

wherein Y═NO 2 , R═C(O)R 1 , R 1 ═CH 2 CH 3 , and X═I, or a pharmaceutically acceptable salt thereof,

wherein said composition contacts a cancer cell or tumor in said mammal, thereby making said cancer cell or tumor more susceptible to the effects of ionizing radiation,

wherein said cancer is at least one selected from the group consisting of glioma, colorectal cancer and non-small cell lung cancer.

5. The method of claim 4 , wherein said composition is administered before, during, or after said mammal receives radiation therapy, or a combination thereafter.

6. The method of claim 4 , wherein said mammal is a human.

7. A method of treating a mammal diagnosed with cancer, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising Formula I,

wherein Y═NO 2 , R═S(O) 2 R 1 , R 1 ═CH 2 CH 3 , and X═F or I, or a pharmaceutically acceptable salt thereof,

wherein said composition contacts a cancer cell or tumor in said mammal, thereby making said cancer cell or tumor more susceptible to the effects of ionizing radiation

wherein said cancer is at least one selected from the group consisting of glioma, colorectal cancer and non-small cell lung cancer.

8. The method of claim 7 , wherein said composition is administered before, during, or after said mammal receives radiation therapy, or a combination thereafter.

9. The method of claim 7 , wherein said mammal is a human.

10. A method of treating a mammal diagnosed with cancer, said method comprising administering to said mammal a therapeutically effective amount of a composition comprising Formula I,

Y═NO 2 , R═P(O)(OH)R 1 , R 1 ═CH 2 CH 3 , and X═F, Cl, Br, H, or I, or a pharmaceutically acceptable salt thereof,

wherein said composition contacts a cancer cell or tumor in said mammal, thereby making said cancer cell or tumor more susceptible to the effects of ionizing radiation,

wherein said cancer is at least one selected from the group consisting of glioma, colorectal cancer and non-small cell lung cancer.

11. The method of claim 10 , wherein said composition is administered before, during, or after said mammal receives radiation therapy, or a combination thereafter.

12. The method of claim 10 , wherein said mammal is a human.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2011
From: KRIDEL, STEVEN
To: WAKE FOREST UNIVERSITY HEALTH SCIENCES
Reel/Frame 026085/0038 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2011
From: KOUMENIS, CONSTANTINOS; LALLY, BRIAN E.; KAO, GARY D.
To: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Reel/Frame 026085/0041 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2011
From: ADEJARE, ADEBOYE
To: UNIVERSITY OF THE SCIENCES IN PHILADELPHIA
Reel/Frame 026085/0084 →
CONFIRMATORY LICENSE Recorded Sep 7, 2010
From: UNIVERSITY OF PENNSYLVANIA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024941/0991 →
Continuity (3)
Provisional Application 61004386 · Nov 27, 2007
Provisional Application 60993776 · Sep 14, 2007
Related Publication 20110190400A1 · Aug 4, 2011